EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey

Olga Martínez-Sáez, Javier Cortés, Eva Ciruelos, Mercedes Marín-Aguilera, Gloria González, Laia Paré, Adriana Herrera, Patricia Villagrasa-González, Aleix Prat, Miguel Martín

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03409-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Olga Martínez-Sáez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Reveal Genomics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to investigate the current therapeutic management of patients with early-stage HER2-positive (HER2+) breast cancer in Spain, while also exploring the perceptions surrounding HER2DX in terms of its credibility, clinical relevance, and impact on therapeutic decision-making. Understanding these aspects is crucial for optimizing treatment strategies and enhancing patient outcomes in the context of HER2+ breast cancer.

Methods

An online questionnaire was conducted by an independent third-party between April and May 2022 across 70 medical oncologists highly specialized in breast cancer management in Spain. The survey included 37 questions regarding treatment decision making in HER2+ early breast cancer.

Results

The management of patients with HER2+ early breast cancer exhibited a high degree of heterogeneity. Among the interviewed oncologists, 53% would recommend upfront surgery for node negative tumors measuring 1 cm or less. Interestingly, 69% and 56% of interviewers were open to deescalate the duration of adjuvant trastuzumab in pT1a and pT1b N0 tumors, respectively. Certain clinicopathological characteristics, such as high grade, high Ki-67, and young age, influenced the decision to prescribe neoadjuvant treatment for patients with clinical stage 1 disease. In cases where neoadjuvant treatment was prescribed for cT1-2 N0 tumors, there was a wide variation in the choice of chemotherapeutic and anti-HER2 regimens. Regarding the use of adjuvant trastuzumab emtansine (T-DM1) in patients with residual disease after neoadjuvant therapy, there was diversity in practice, and a common concern emerged that T-DM1 might be overtreating some patients. HER2DX, as a diagnostic tool, was deemed trustworthy, and the reported scores were considered clinically useful. However, 86% of interviewees believed that a prospective trial was necessary before fully integrating the test into routine clinical practice.

Conclusion

In the context of early-stage HER2+ breast cancer in Spain, a notable diversity in therapeutic approaches was observed. The majority of interviewed medical oncologists acknowledged HER2DX as a clinically valuable test for specific patients, in line with the 2022 SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer. To facilitate the full integration of HER2DX into clinical guidelines, conducting prospective studies to further validate its efficacy and utility was recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansFemaleSpainSurveys and QuestionnairesPractice Patterns, Physicians'TrastuzumabAttitude of Health PersonnelClinical Decision-MakingNeoplasm StagingMiddle AgedChemotherapy, AdjuvantAntineoplastic Agents, ImmunologicalAdo-Trastuzumab EmtansineAdult

Stichwörter der Autor:innen

Breast cancerGenomicHER2HER2DXNeoadjuvantPertuzumabT-DM1Trastuzumab

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabAntineoplastic Agents, ImmunologicalAdo-Trastuzumab EmtansineERBB2 protein, human

Autor:innen und Institutionen

  • Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Department of Medicine, University of Barcelona, Barcelona, Spain.
  • International Breast Cancer Center, Pangaea Oncology Quironsalud Group, Barcelona, Spain.
  • Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain.
  • Department of Medical Oncology, Hospital Universitario, 12 de Octubre, Madrid, Spain.

Förderung

  • Reveal Genomics

Zitieren

APA

Martínez-Sáez, O., Cortés, J., Ciruelos, E., Marín-Aguilera, M., González, G., Paré, L., Herrera, A., Villagrasa-González, P., Prat, A., & Martín, M. (2024). Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03409-4

Vancouver

Martínez-Sáez O, Cortés J, Ciruelos E, Marín-Aguilera M, González G, Paré L, et al. Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03409-4

BibTeX
@article{MartnezSez2024,
  author = {Martínez-Sáez, Olga and Cortés, Javier and Ciruelos, Eva and Marín-Aguilera, Mercedes and González, Gloria and Paré, Laia and Herrera, Adriana and Villagrasa-González, Patricia and Prat, Aleix and Martín, Miguel},
  title = {Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03409-4}
}
Kostenlos starten →